A real world study assessing treatment sequencing and duration of subsequent tyrosine kinase inhibitors for Brigatinib in the treatment of Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Sep 2022 Results evaluating efficacy and tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer, published in the Oncologist
- 24 Nov 2021 New trial record